Platform Licensing Pear Bio’s proprietary computational biology platform deconvolutes cancer biology using 3D immune-microtumors and image-based biomarkers to predict patient-specific treatment efficacy, presenting a clear path to license or co-develop access for pharma/biotech clients seeking precision medicine tooling.

Clinical Trial Partnerships The February 2024 UK observational brain tumor trial demonstrates readiness to collaborate with hospitals and academic centers, offering opportunities to provide ex vivo drug testing services, outcome analytics, and biomarker-informed decision support as a service to clinical networks.

Biomarker Partnerships A multi-omics pipeline for discovering novel drug targets in non-responders supports potential partnerships in target validation, biomarker development, and integration with partner drug discovery programs.

Investor Backing With Series A funding and a lean, agile team, Pear Bio is well-positioned to pursue partnerships across oncology with speed, offering flexible collaboration models and rapid pilots to de-risk drug development for pharma and biotech.

Tech Differentiator Pear Bio’s deep integration of microphysiological systems, time-course 3D microscopy, and DL-based image biomarker analysis creates a distinctive value proposition for partners seeking fast, patient-centric decision support and companion diagnostics.